Início › Linfoma de Burkitt › Alabama
Ensaios clínicos de Linfoma de Burkitt em Alabama
7 estudos para Linfoma de Burkitt estão buscando participantes em locais em Alabama.
Cidades em Alabama
Texto oficial do estudo (Inglês)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
RecrutandoFase 2
366 Days – 46 Years · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital of Alabama, Birmingham
RecrutandoFase 2
365 Days · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
RecrutandoFase 2
Idades de 1 a 30 · Todos os sexos · Atualizado em 1 de set. de 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital of Alabama, Birmingham
- USA Health Strada Patient Care Center, Mobile
RecrutandoFase 3
365 Days – 25 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT03959085Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- University of Alabama at Birmingham, Birmingham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 5 de nov. de 2025 · NCT04260022The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's of Alabama/University of Alabama in Birmingham(UAB), Birmingham
RecrutandoFase 2
Idades de 1 a 25 · Todos os sexos · Atualizado em 4 de mai. de 2025 · NCT03509961Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 15 de nov. de 2024 · NCT06034275Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.